We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Awareness Technology, Inc.

Awareness Technology, Inc. provides clinical laboratory instrumentation, reagents and assays for small-to-medium-volu... read more Featured Products: More products

Download Mobile App




Awareness Technology Announces ChemWell RPR Analyzer - The Most Significant Innovation in Syphilis Testing in Last 30 Years

By LabMedica International staff writers
Posted on 17 Jul 2020
Print article
Image: ChemWell RPR Analyzer (Photo courtesy of Awareness Technology, Inc.)
Image: ChemWell RPR Analyzer (Photo courtesy of Awareness Technology, Inc.)
Awareness Technology, Inc. (Palm City, FL, USA) has announced the most significant innovation in syphilis testing in the last 30 years with the launch of the ChemWell RPR automated nontreponemal analyzer for the detection of syphilis.

Awareness is an international IVD company that develops, manufactures, and markets high quality in-vitro diagnostic instrumentation, and diagnostic test kits. The company’s instrument portfolio includes biochemistry, ELISA, chemiluminescence, imaging analytics, electrolyte instruments, and supportive equipment. Awareness’ diagnostic test kit portfolio includes ELISA kits with a focus on autoimmune and infectious disease testing, biochemistry test kits, and allergy screening kits, which support over 200 specific allergens.

Laboratories can now automate nontreponemal testing and drive significant operational efficiencies while minimizing false-positive results with Awareness’ ChemWell RPR automated nontreponemal analyzer for the detection of syphilis. Designed to work with carbon antigen, the RPR analyzer uses four standard 48 well microwell plates instead of manual RPR cards to analyze up to 192 samples per hour without any user intervention. It utilizes a high resolution imaging system which captures the reaction taking place in each of the back-lit wells that are interpreted by a proven algorithm and provide an accurate and reliable negative or positive result based on the captured images. It can perform visual identification of positive or negative reaction with a sensitivity of 98.8% and a specificity of 99.8%.

An additional test can be run on positive samples to determine titers up to 1:2048 dilution for therapeutic monitoring. The software is included with the user-friendly system at no additional cost and features an intuitive interface that allows for easy navigation and use. Automated features such as fluid handling, mixing, timing, image capture, image processing, and reporting are all handled by the software.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.